Unicycive Affirms Path Forward for Kidney Drug OLC After FDA Letter

MOUNTAIN VIEW, CA – June 30, 2026 – Unicycive Therapeutics, a biotechnology company dedicated to developing novel treatments for kidney disease, today reaffirmed its confidence in its lead investigational drug, oxylanthanum carbonate (OLC), following the receipt of a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA). The letter pertains to the company’s resubmitted New Drug Application (NDA) for OLC for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis.

Crucially, the FDA’s letter did not raise any concerns regarding the clinical efficacy or safety data of OLC, nor did it request any new clinical studies. The CRL is focused exclusively on previously identified deficiencies at a third-party manufacturing facility. Unicycive is actively engaged with the FDA and the manufacturing partner to resolve the outstanding issues and clear the path for OLC’s approval.

“We remain confident in the efficacy and safety of OLC,” said Shalabh Gupta, M.D., Chief Executive Officer of Unicycive. “We are in active and ongoing discussion with the FDA regarding label and packaging, and we are optimistic that there will be a successful inspection of the third-party manufacturing vendor and that we will be able to expeditiously resubmit the NDA.”

A Breakthrough Therapy Meets a Common Hurdle

Hyperphosphatemia, or elevated phosphate levels in the blood, is a near-universal and dangerous complication for the more than 450,000 people in the U.S. with End-Stage Renal Disease (ESRD). When failing kidneys can no longer filter phosphate, its buildup is strongly associated with increased hospitalization and mortality. The standard of care involves a restrictive diet and a regimen of oral phosphate-binding drugs taken with every meal.

However, patient adherence to these treatments is notoriously challenging. Many existing therapies require patients to consume a large number of sizable pills daily, creating a significant “pill burden” that can compromise treatment effectiveness. Unicycive’s OLC was specifically designed to address this critical unmet need. By leveraging proprietary nanoparticle technology, OLC is engineered to deliver high phosphate-binding potency in smaller, fewer pills.

The potential for OLC to improve patient adherence and outcomes is supported by a robust data package, including multiple clinical and preclinical studies. The FDA’s explicit confirmation that the CRL is unrelated to this clinical data underscores the fundamental strength of the therapy itself. The delay, while frustrating for the company and the patients it aims to serve, stems from a common and addressable aspect of the drug approval process: manufacturing compliance. Regulatory experts note that issues related to Chemistry, Manufacturing, and Controls (CMC) are frequently cited in CRLs, with some analyses showing that quality or manufacturing deficiencies contribute to over 70% of such letters in recent years.

Navigating the Regulatory Pathway with Confidence

This is the second CRL Unicycive has received related to this specific third-party manufacturing vendor, with the first issued in June 2025. Following the initial letter, Unicycive took proactive steps to chart a clear path forward. The company held a Type A meeting with the FDA in September 2025 to gain alignment on resolving the cited deficiencies. During that meeting, the FDA did not express concerns about the vendor’s stated progress, giving the company a basis for its resubmission.

Unicycive has noted that the FDA did not conduct a new inspection of the third-party facility during the most recent review cycle. A successful future inspection is the critical next step. The company's ongoing dialogue with the agency, including recent communications as of June 29 regarding carton and container labeling, is a positive sign of continued engagement and progress on non-manufacturing components of the application. This suggests that once the manufacturing compliance is verified, other key aspects of the NDA are already well advanced in the review process.

Unicycive is seeking approval for OLC via the 505(b)(2) regulatory pathway, which allows for the use of existing data from a previously approved drug, streamlining the development process. Furthermore, OLC is protected by a strong global patent portfolio, including issued composition of matter patents that provide exclusivity until at least 2031, with the potential for term extensions until 2035. This long-term intellectual property protection reinforces the enduring value of the asset as the company works to resolve the current manufacturing delay.

The Critical Importance of Manufacturing Excellence

The FDA’s intense focus on manufacturing is a cornerstone of its public health mission. The agency’s Current Good Manufacturing Practices (cGMP) regulations are designed to guarantee that every batch of an approved drug is safe, effective, and of the highest quality. These rules govern everything from facility design and equipment maintenance to process controls and quality management systems. For a drug sponsor like Unicycive, ensuring that its contract manufacturing partners meet these exacting standards is a non-negotiable part of bringing a new therapy to market.

The FDA holds the drug sponsor ultimately responsible for the quality of its product, regardless of where it is manufactured. This regulatory framework ensures accountability and forces rigorous oversight of the entire supply chain. While a CRL related to manufacturing can cause delays, it also serves as a critical quality checkpoint. It demonstrates the FDA’s diligence in preventing potentially substandard products from reaching patients. For Unicycive, addressing these cGMP deficiencies is now the primary focus, a task that, once completed, will result in a more robust and resilient supply chain for OLC upon its eventual launch.

An Unwavering Commitment to the Kidney Disease Community

Behind the regulatory processes and manufacturing logistics lies a clear and urgent human need. Patients on dialysis already face immense daily challenges, and the high pill burden associated with managing hyperphosphatemia only adds to their struggle. The promise of OLC lies in its potential to significantly ease this burden, making a life-sustaining treatment easier to tolerate and adhere to. This could translate directly into better health outcomes and an improved quality of life for a large and vulnerable patient population.

Unicycive’s mission extends across the spectrum of kidney disease. Beyond OLC, the company is advancing its second investigational treatment, UNI-494, which is being developed for acute kidney injury and has already received Orphan Drug Designation from the FDA. This broader pipeline reflects a deep-seated commitment to addressing the complex challenges faced by patients with renal conditions.

The company remains steadfast in its goal to bring OLC to market. The path to drug approval is often complex, with non-clinical hurdles being a frequent part of the journey. By working diligently with its partners and the FDA, Unicycive is focused on completing the final steps required to deliver its innovative therapy to the thousands of patients waiting for a better treatment option.